NASDAQ:CGTX Cognition Therapeutics (CGTX) Stock Price, News & Analysis $0.96 +0.01 (+0.59%) Closing price 04:00 PM EasternExtended Trading$0.97 +0.01 (+0.83%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Cognition Therapeutics Stock (NASDAQ:CGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cognition Therapeutics alerts:Sign Up Key Stats Today's Range$0.96▼$0.9850-Day Range$0.89▼$1.1352-Week Range$0.55▼$2.05Volume386,107 shsAverage Volume390,705 shsMarket Capitalization$91.29 millionP/E RatioN/ADividend YieldN/APrice Target$3.33Consensus RatingModerate Buy Company Overview Cognition Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing medicines for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as SIGMAR2, a protein believed to play a role in the cellular processes associated with cognitive decline and neurodegeneration. Cognition Therapeutics’ lead product candidate is CT1812, an orally administered, brain-penetrant small molecule designed to modulate SIGMAR2. The investigational therapy is being evaluated for Alzheimer’s disease and other forms of dementia, including dementia with Lewy bodies. CT1812 has not been approved for commercial use, and its safety and effectiveness remain under evaluation in clinical trials. Founded in 2007, Cognition Therapeutics conducts its research and clinical development activities primarily in the United States. The company is headquartered in Purchase, New York, and is led by President and Chief Executive Officer Lisa K. Miller.AI Generated. May Contain Errors. Read More Cognition Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreCGTX MarketRank™: Cognition Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 603rd out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCognition Therapeutics has a consensus price target of $3.33, representing about 247.2% upside from its current price of $0.96.Amount of Analyst CoverageCognition Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cognition Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cognition Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.16% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 22.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 1.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.76 News SentimentCognition Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cognition Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.11% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cognition Therapeutics' insider trading history. Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGTX Stock News HeadlinesCognition Set For Type C FDA Meeting In Oct '26 On Planned Phase 3 For Dementia Drug ZervimesineSeptember 29 at 10:24 PM | rttnews.comCognition Therapeutics Schedules FDA Type C Meeting to Discuss Phase 3 Trial Endpoint for Zervimesine in Dementia with Lewy BodiesSeptember 29 at 7:51 AM | quiverquant.comQTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may be a bid to reset the US dollar. Porter Stansberry says the meeting, attended by figures like Elon Musk, Jensen Huang and Larry Fink, connects to a 13-nation pact designed to cut China out of a massive investment wave.September 30 at 1:00 AM | Porter & Company (Ad)Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLBSeptember 29 at 7:30 AM | globenewswire.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $3.33 Consensus Target Price from AnalystsSeptember 23, 2026 | americanbankingnews.comCognition Therapeutics to Present Zervimesine Development Progress at H.C. Wainwright Global Investment ConferenceSeptember 8, 2026 | quiverquant.comQCognition Therapeutics to Present at H.C. Wainwright Global Investment ConferenceSeptember 8, 2026 | globenewswire.comCognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business UpdateAugust 6, 2026 | markets.businessinsider.comSee More Headlines CGTX Stock Analysis - Frequently Asked Questions How have CGTX shares performed this year? Cognition Therapeutics' stock was trading at $1.35 at the start of the year. Since then, CGTX stock has decreased by 28.9% and is now trading at $0.96. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. When did Cognition Therapeutics IPO? Cognition Therapeutics (CGTX) raised $45 million in an IPO on Thursday, October 7th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cognition Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), GE Aerospace (GE), Arista Networks (ANET) and Celestica (CLS). Company Calendar Last Earnings8/06/2026Today9/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CGTX's financial health is in the Yellow zone, according to TradeSmith. CGTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CGTX CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees14Year Founded2007Price Target and Rating Average Price Target for Cognition Therapeutics$3.33 High Price Target$4.00 Low Price Target$3.00 Potential Upside/Downside+247.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.17% Return on Assets-40.22% Debt Debt-to-Equity RatioN/A Current Ratio7.03 Quick Ratio7.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book2.46Miscellaneous Outstanding Shares95,094,000Free Float84,529,000Market Cap$91.29 million OptionableNot Optionable Beta1.79 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CGTX) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredNot SpaceX. Not Tesla. Smaller.SpaceX isn't public, but its paperwork references a company trading for about 14 dollars a share. Roughly 4,40...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
